The global assisted reproductive technology market was valued at $2,317.7 million in 2020, and is estimated to reach $12,272.5 million by 2030, growing at a CAGR of 19.3% from 2021 to 2030.
Assisted reproductive technology (ART) is defined as the medical procedure used to address the infertility treatments for handling of eggs and embryo. This technique aims to remove the eggs from a woman’s ovaries and further combine it with sperm in the in-vitro laboratory condition. After fertilization, the egg or embryo is transferred to the uterus of women. It alleviates the burden of infertility on a family and individual. In-vitro technology is one of the most common and advanced procedures, which are used for the infertility treatment. The ART includes gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), zygote intrafallopian transfer and in vitro fertilization-embryo transfer.
The global assisted reproductive technology market is majorly driven by an alarming increase in the prevalence of polycystic ovary syndrome, rise in disposable income, surge in demand for in vitro-fertilization, advancement in the technology for novel ART, and a rise in awareness about IVF and surrogacy. According to Office on Women’s Health (OASH), in 2019, it was reported that 1 in 10 women of childbearing age are diagnosed with PCOS, in the U.S. According to Center for Disease control and Prevention (CDC), it was reported that 6% to 12% of the U.S. women of reproductive age, having PCOS, were also diagnosed with infertility. PCOS is one of the most common causes of female infertility, which surge the demand for assisted reproductive technology and drive the growth of the market. The rise in disposable income has assisted reproductive technology and drives the growth of the market. Furthermore, in February 2021, TMRW Life Sciences, announced the launch of the world’s first automated Cryo specimen management solution for eggs and embryo, which are used in the IVF procedure. The TMRW platform is introduced in various fertility clinics in the U.S. launching the software enables management of the million embryos and eggs central to modern IVF.
Increase in incidence of infertility cases and the surge in sedentary lifestyle are the major factors that drive the global assisted reproductive technology market. Moreover, the increase in prevalence of obesity significantly contributes toward the market growth, owing to obese person being more prone to infertility and uterine disorder. Rise in demand for in-vitro fertilization for effective treatment, and high success rate acts a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support healthcare information systems for development of advanced ART, which is expected to boost the market growth. As per a study by the American Society for reproductive medicines, it was reported that approximately 40% of infertile couple, the male partner is responsible for infertility and among them 85% to 90% are treated with surgery. In addition, technological advancements in assisted reproductive technology, and growth in number of fertility clinic are anticipated to provide lucrative opportunities for the market expansion. The rise in awareness regarding cost-effective treatment of infertility and spread of knowledge about the success rate of IVF procedure propels the growth of the market.
On the contrary, risk associated after IVF procedure and high cost of assisted reproductive technology are anticipated to hinder the market growth during the forecast period. The rise in number of fertility clinic and development of IVD devices leads to the enhancement of the assisted reproductive technology sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the assisted reproductive technology market.
The global assisted reproductive technology market is segmented into product, technology, end user, and region. By product, the market is categorized into instrument, accessory & disposable, and reagent & media.
Some of the major companies that operate in the global assisted reproductive technology market are Cook Medical Inc., Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.), Genea Biomedx, Merck KGaA (EMD Serono, Inc.), Millendo Therapeutics, Inc., Oxford Gene Technology, Progyny Inc., The Cooper Companies, Inc. (CooperSurgical, Inc.), Thermo Fisher Scientific, Inc., Vitrolife AB.
Assisted reproductive technology (ART) is defined as the medical procedure used to address the infertility treatments for handling of eggs and embryo. This technique aims to remove the eggs from a woman’s ovaries and further combine it with sperm in the in-vitro laboratory condition. After fertilization, the egg or embryo is transferred to the uterus of women. It alleviates the burden of infertility on a family and individual. In-vitro technology is one of the most common and advanced procedures, which are used for the infertility treatment. The ART includes gamete intrafallopian transfer (GIFT), frozen embryo transfer (FET), zygote intrafallopian transfer and in vitro fertilization-embryo transfer.
The global assisted reproductive technology market is majorly driven by an alarming increase in the prevalence of polycystic ovary syndrome, rise in disposable income, surge in demand for in vitro-fertilization, advancement in the technology for novel ART, and a rise in awareness about IVF and surrogacy. According to Office on Women’s Health (OASH), in 2019, it was reported that 1 in 10 women of childbearing age are diagnosed with PCOS, in the U.S. According to Center for Disease control and Prevention (CDC), it was reported that 6% to 12% of the U.S. women of reproductive age, having PCOS, were also diagnosed with infertility. PCOS is one of the most common causes of female infertility, which surge the demand for assisted reproductive technology and drive the growth of the market. The rise in disposable income has assisted reproductive technology and drives the growth of the market. Furthermore, in February 2021, TMRW Life Sciences, announced the launch of the world’s first automated Cryo specimen management solution for eggs and embryo, which are used in the IVF procedure. The TMRW platform is introduced in various fertility clinics in the U.S. launching the software enables management of the million embryos and eggs central to modern IVF.
Increase in incidence of infertility cases and the surge in sedentary lifestyle are the major factors that drive the global assisted reproductive technology market. Moreover, the increase in prevalence of obesity significantly contributes toward the market growth, owing to obese person being more prone to infertility and uterine disorder. Rise in demand for in-vitro fertilization for effective treatment, and high success rate acts a key driving force of the global market. Furthermore, governments are taking multiple initiatives to support healthcare information systems for development of advanced ART, which is expected to boost the market growth. As per a study by the American Society for reproductive medicines, it was reported that approximately 40% of infertile couple, the male partner is responsible for infertility and among them 85% to 90% are treated with surgery. In addition, technological advancements in assisted reproductive technology, and growth in number of fertility clinic are anticipated to provide lucrative opportunities for the market expansion. The rise in awareness regarding cost-effective treatment of infertility and spread of knowledge about the success rate of IVF procedure propels the growth of the market.
On the contrary, risk associated after IVF procedure and high cost of assisted reproductive technology are anticipated to hinder the market growth during the forecast period. The rise in number of fertility clinic and development of IVD devices leads to the enhancement of the assisted reproductive technology sector. This encourages many key players to enter emerging markets, thus offering a lucrative growth opportunity in the assisted reproductive technology market.
The global assisted reproductive technology market is segmented into product, technology, end user, and region. By product, the market is categorized into instrument, accessory & disposable, and reagent & media.
By technology, it is divided into in vivo-fertilization, artificial insemination, others. By end user, the market is bifurcated into fertility clinic, hospital, surgical center, clinical research institute. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global assisted reproductive technology market are Cook Medical Inc., Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.), Genea Biomedx, Merck KGaA (EMD Serono, Inc.), Millendo Therapeutics, Inc., Oxford Gene Technology, Progyny Inc., The Cooper Companies, Inc. (CooperSurgical, Inc.), Thermo Fisher Scientific, Inc., Vitrolife AB.
KEY BENEFITS FOR STAKEHOLDERS
- The report provides an in-depth analysis of the global assisted reproductive technology market size along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
- A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global assisted reproductive technology market.
KEY MARKET SEGMENTS
By Product
- Instrument
- Sperm Separation System
- Cryosystem
- Incubator
- Imaging System
- Ovum Aspiration Pump
- Cabinet
- Micromanipulator
- Laser Systems
- Others
- Accessory & Disposable
- Reagents & Media
- Cryopreservation Media
- Semen Processing Media
- Ovum Processing Media
- Embryo Culture Media
By Technology
- In Vitro-Fertilization
- Artificial Insemination
- Others
By End User
- Fertility Clinic
- Hospital
- Surgical Center
- Clinical Research Institute
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
KEY MARKET PLAYERS
- Cook Medical Inc.
- Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.)
- Genea Biomedx
- Merck KGaA (EMD Serono, Inc.)
- Millendo Therapeutics, Inc.
- Oxford Gene Technology
- Progyny Inc.
- The Cooper Companies, Inc. (CooperSurgical, Inc.)
- Thermo Fisher Scientific, Inc.
- Vitrolife AB.
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Increase in prevalence of infertility rate
3.5.1.2. Technological advancements in assisted reproductive technology
3.5.1.3. Growth in disposable income and rise in awareness regarding infertility treatment
3.5.2. Restraint
3.5.2.1. High cost of ART procedure
3.5.2.2. Risk associated with IVF treatment
3.5.3. Opportunity
3.5.3.1. Growing opportunities in emerging market and rise in fertility tourism
3.5.4. Impact analysis
3.6. Impact analysis of COVID-19 on the assisted reproductive technology market
CHAPTER 4: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT4.1. Overview
4.1.1. Market size and forecast
4.2. Instrument
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Instrument, by type
4.2.2.1. Market size and forecast
4.2.2.2. Sperm separation system
4.2.2.2.1. Market size and forecast
4.2.2.3. Cryosystem
4.2.2.3.1. Market size and forecast
4.2.2.4. Incubator
4.2.2.4.1. Market size and forecast
4.2.2.5. Imaging system
4.2.2.5.1. Market size and forecast
4.2.2.6. Ovum aspiration pump
4.2.2.6.1. Market size and forecast
4.2.2.7. Cabinet
4.2.2.7.1. Market size and forecast
4.2.2.8. Micromanipulator
4.2.2.8.1. Market size and forecast
4.2.2.9. Laser systems
4.2.2.9.1. Market size and forecast
4.2.2.10. Others
4.2.2.10.1. Market size and forecast
4.2.3. Market size and forecast, by region
4.2.4. Market analysis, by country
4.3. Accessory & Disposable
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Reagent & Media
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Reagent & Media, by type
4.4.2.1. Market size and forecast
4.4.2.2. Cryopreservation Media
4.4.2.2.1. Market size and forecast
4.4.2.3. Semen processing media
4.4.2.3.1. Market size and forecast
4.4.2.4. Ovum processing media
4.4.2.4.1. Market size and forecast
4.4.2.5. Embryo culture media
4.4.2.5.1. Market size and forecast
4.4.3. Market size and forecast, by region
4.4.4. Market analysis, by country
CHAPTER 5: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY5.1. Overview
5.1.1. Market size and forecast
5.2. In vitro-fertilization
5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country
5.3. Artificial Insemination
5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market analysis, by country
5.4. Others
5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market analysis, by country
CHAPTER 6: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER6.1. Overview
6.1.1. Market size and forecast
6.2. Fertility clinics
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market analysis, by country
6.3. Hospital
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market analysis, by country
6.4. Surgical center
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market analysis, by country
6.5. Clinical research institute
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market analysis, by country
CHAPTER 7: ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION7.1. Overview
7.1.1. Market size and forecast'
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America assisted reproductive technology market, by product
7.2.3. North America assisted reproductive technology market, by technology
7.2.4. North America assisted reproductive technology market, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. U.S. assisted reproductive technology market, by product
7.2.5.1.2. U.S. assisted reproductive technology market, by technology
7.2.5.1.3. U.S. assisted reproductive technology market, by end user
7.2.5.2. Canada
7.2.5.2.1. Canada assisted reproductive technology market, by product
7.2.5.2.2. Canada assisted reproductive technology market, by technology
7.2.5.2.3. Canada assisted reproductive technology market, by end user
7.2.5.3. Mexico
7.2.5.3.1. Mexico assisted reproductive technology market, by product
7.2.5.3.2. Mexico assisted reproductive technology market, by technology
7.2.5.3.3. Mexico assisted reproductive technology market, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe assisted reproductive technology market, by product
7.3.3. Europe assisted reproductive technology market, by technology
7.3.4. Europe assisted reproductive technology market, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Germany assisted reproductive technology market, by product
7.3.5.1.2. Germany assisted reproductive technology market, by technology
7.3.5.1.3. Germany assisted reproductive technology market, by end user
7.3.5.2. France
7.3.5.2.1. France assisted reproductive technology market, by product
7.3.5.2.2. France assisted reproductive technology market, by technology
7.3.5.2.3. France assisted reproductive technology market, by end user
7.3.5.3. UK
7.3.5.3.1. UK assisted reproductive technology market, by product
7.3.5.3.2. UK assisted reproductive technology market, by technology
7.3.5.3.3. UK assisted reproductive technology market, by end user
7.3.5.4. Italy
7.3.5.4.1. Italy assisted reproductive technology market, by product
7.3.5.4.2. Italy assisted reproductive technology market, by technology
7.3.5.4.3. Italy assisted reproductive technology market, by end user
7.3.5.5. Spain
7.3.5.5.1. Spain assisted reproductive technology market, by product
7.3.5.5.2. Spain assisted reproductive technology market, by technology
7.3.5.5.3. Spain assisted reproductive technology market, by end user
7.3.5.6. Rest of Europe
7.3.5.6.1. Rest of Europe assisted reproductive technology market, by product
7.3.5.6.2. Rest of Europe assisted reproductive technology market, by technology
7.3.5.6.3. Rest of Europe assisted reproductive technology market, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific assisted reproductive technology market, by product
7.4.3. Asia-Pacific assisted reproductive technology market, by technology
7.4.4. Asia-Pacific assisted reproductive technology market, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Japan assisted reproductive technology market, by product
7.4.5.1.2. Japan assisted reproductive technology market, by technology
7.4.5.1.3. Japan assisted reproductive technology market, by end user
7.4.5.2. China
7.4.5.2.1. China assisted reproductive technology market, by product
7.4.5.2.2. China assisted reproductive technology market, by technology
7.4.5.2.3. China assisted reproductive technology market, by end user
7.4.5.3. India
7.4.5.3.1. India assisted reproductive technology market, by product
7.4.5.3.2. India assisted reproductive technology market, by technology
7.4.5.3.3. India assisted reproductive technology market, by end user
7.4.5.4. Australia
7.4.5.4.1. Australia assisted reproductive technology market, by product
7.4.5.4.2. Australia assisted reproductive technology market, by technology
7.4.5.4.3. Australia assisted reproductive technology market, by end user
7.4.5.5. South Korea
7.4.5.5.1. South Korea assisted reproductive technology market, by product
7.4.5.5.2. South Korea assisted reproductive technology market, by technology
7.4.5.5.3. South Korea assisted reproductive technology market, by end user
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Rest of Asia-Pacific assisted reproductive technology market, by product
7.4.5.6.2. Rest of Asia-Pacific assisted reproductive technology market, by technology
7.4.5.6.3. Rest of Asia-Pacific assisted reproductive technology market, by end user
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA assisted reproductive technology market, by product
7.5.3. LAMEA assisted reproductive technology market, by technology
7.5.4. LAMEA assisted reproductive technology market, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Brazil assisted reproductive technology market, by product
7.5.5.1.2. Brazil assisted reproductive technology market, by technology
7.5.5.1.3. Brazil assisted reproductive technology market, by end user
7.5.5.2. Saudi Arabia
7.5.5.2.1. Saudi Arabia assisted reproductive technology market, by product
7.5.5.2.2. Saudi Arabia assisted reproductive technology market, by technology
7.5.5.2.3. Saudi Arabia assisted reproductive technology market, by end user
7.5.5.3. South Africa
7.5.5.3.1. South Africa assisted reproductive technology market, by product
7.5.5.3.2. South Africa assisted reproductive technology market, by technology
7.5.5.3.3. South Africa assisted reproductive technology market, by end user
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Rest of LAMEA assisted reproductive technology market, by product
7.5.5.4.2. Rest of LAMEA assisted reproductive technology market, by technology
7.5.5.4.3. Rest of LAMEA assisted reproductive technology market, by end user
CHAPTER 8: COMPANY PROFILES8.1. COOK GROUP
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Key strategic moves and developments
8.2. FUJIFILM HOLDINGS CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. GENEA BIOMEDX
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Key strategic moves and developments
8.4. MERCK KGAA
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. INCEPTION SCIENCES, INC.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.6. OXFORD GENE TECHNOLOGY IP LTD.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.7. PROGYNY INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. THE COOPER COMPANIES, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. THERMO FISHER SCIENTIFIC, INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. VITROLIFE AB
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
List of Tables
TABLE 01. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 02. INSTRUMENT MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 03. INSTRUMENT ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04. ACCESSORY & DISPOSABLE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. REAGENT & MEDIA MARKET, BY TYPE, 2020-2030 ($MILLION)
TABLE 06. REAGENT & MEDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 08. IN VITRO-FERTILIZATION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 09. ARTIFICIAL INSEMINATION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 10. OTHERS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 12. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FERTILITY CLINIC, BY REGION, 2020-2030 ($MILLION)
TABLE 13. HOSPITAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14. SURGICAL CENTER ASSISTED REPRODUCTIVE TECHNOLOGY, BY REGION, 2020-2030 ($MILLION)
TABLE 15. CLINICAL RESEARCH INSTITUTE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 16. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 18. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 19. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 20. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 21. U.S. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 22. U.S. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 23. U.S. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24. CANADA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25. CANADA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 26. CANADA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 27. MEXICO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 28. MEXICO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 29. MEXICO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 30. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 31. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 32. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 33. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 34. GERMANY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 35. GERMANY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 36. GERMANY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 37. FRANCE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 38. FRANCE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 39. FRANCE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 40. UK ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41. UK ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 42. UK ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. ITALY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 44. ITALY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 45. ITALY ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 46. SPAIN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 47. SPAIN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 48. SPAIN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 49. REST OF EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 50. REST OF EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 51. REST OF EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 52. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 53. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 54. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 55. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 56. JAPAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 57. JAPAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 58. JAPAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 59. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 60. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 61. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 62. INDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 63. INDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 64. INDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65. AUSTRALIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 66. AUSTRALIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 67. AUSTRALIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 68. SOUTH KOREA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 69. SOUTH KOREA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 70. SOUTH KOREA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 74. LAMEA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 75. LAMEA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 76. LAMEA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 77. LAMEA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 78. BRAZIL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 79. BRAZIL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 80. BRAZIL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 81. SAUDI ARABIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 82. SAUDI ARABIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 83. SAUDI ARABIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 84. SOUTH AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 85. SOUTH AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 86. SOUTH AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 87. REST OF LAMEA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 88. REST OF LAMEA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
TABLE 89. REST OF LAMEA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 90. COOK: COMPANY SNAPSHOT
TABLE 91. COOK: OPERATING SEGMENTS
TABLE 92. COOK: PRODUCT PORTFOLIO
TABLE 93. COOK: KEY DEVELOPMENTS
TABLE 94. FUJIFILM: COMPANY SNAPSHOT
TABLE 95. FUJIFILM: OPERATING BUSINESS SEGMENTS
TABLE 96. FUJIFILM: PRODUCT PORTFOLIO
TABLE 97. FUJIFILM: KEY DEVELOPMENTS
TABLE 98. GENEA: COMPANY SNAPSHOT
TABLE 99. GENEA: PRODUCT SEGMENTS
TABLE 100. GENEAE: PRODUCT PORTFOLIO
TABLE 101. GENEA: KEY DEVELOPMENTS
TABLE 102. MERCK: COMPANY SNAPSHOT
TABLE 103. MERCK: OPERATING SEGMENTS
TABLE 104. MERCK: PRODUCT PORTFOLIO
TABLE 105. MERCK: KEY DEVELOPMENTS
TABLE 106. INCEPTION: COMPANY SNAPSHOT
TABLE 107. INCEPTION: OPERATING SEGMENTS
TABLE 108. INCEPTION: PRODUCT PORTFOLIO
TABLE 109. OXFORD: COMPANY SNAPSHOT
TABLE 110. OXFORD: OPERATING BUSINESS SEGMENTS
TABLE 111. OXFORD: PRODUCT PORTFOLIO
TABLE 112. PROGYNY: COMPANY SNAPSHOT
TABLE 113. PROGYNY: OPERATING SEGMENTS
TABLE 114. PROGYNY: PRODUCT PORTFOLIO
TABLE 115. COOPER: COMPANY SNAPSHOT
TABLE 116. COOPER: OPERATING SEGMENTS
TABLE 117. COOPER: PRODUCT PORTFOLIO
TABLE 118. COOPER: KEY DEVELOPMENTS
TABLE 119. THERMO FISHER: COMPANY SNAPSHOT
TABLE 120. THERMO FISHER: OPERATING SEGMENTS
TABLE 121. THERMO FISHER: PRODUCT PORTFOLIO
TABLE 122. VITROLIFE: COMPANY SNAPSHOT
TABLE 123. VITROLIFE: OPERATING SEGMENTS
TABLE 124. VITROLIFE: PRODUCT PORTFOLIO
TABLE 125. VITROLIFE: KEY DEVELOPMENTS
List of Figures
FIGURE 01. ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. HIGH THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE INTENSITY OF RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE ANALYSIS OF INSTRUMENT ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 14. COMPARATIVE ANALYSIS OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR ACCESSORY & DISPOSABLE, BY COUNTRY, 2020-2030 (%)
FIGURE 15. COMPARATIVE ANALYSIS OF REAGENT & MEDIA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 16. COMPARATIVE ANALYSIS OF IN VITRO-FERTILIZATION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 17. COMPARATIVE ANALYSIS OF ARTIFICIAL INSEMINATION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 18. COMPARATIVE ANALYSIS OF OTHERS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, BY COUNTRY, 2020-2030 (%)
FIGURE 19. COMPARATIVE ANALYSIS OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR FERTILITY CLINIC, BY COUNTRY, 2020-2030 (%)
FIGURE 20. COMPARATIVE ANALYSIS OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR HOSPITAL, BY COUNTRY, 2020-2030 (%)
FIGURE 21. COMPARATIVE ANALYSIS OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR SURGICAL CENTER, BY COUNTRY, 2020-2030 (%)
FIGURE 22. COMPARATIVE ANALYSIS OF ASSISTED REPRODUCTIVE TECHNOLOGY MARKET FOR CLINICAL RESEARCH INSTITUTE, BY COUNTRY, 2020-2030 (%)
FIGURE 23. FUJIFILM: NET SALES, 2019-2021 ($MILLION)
FIGURE 24. FUJIFILM: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 25. FUJIFILM: REVENUE SHARE BY REGION, 2021(%)
FIGURE 26. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 27. MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 28. MERCK: REVENUE SHARE BY REGION, 2020(%)
FIGURE 29. PROGYNY: NET SALES, 2018-2020 ($MILLION)
FIGURE 30. COOPER: NET SALES, 2018-2020 ($MILLION)
FIGURE 31. COOPER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32. COOPER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 33. THERMO FISHER: NET SALES, 2018-2020 ($MILLION)
FIGURE 34. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35. THERMO FISHER: REVENUE SHARE BY REGION, 2020(%)
FIGURE 36. VITROLIFE: NET SALES, 2018-2020 ($MILLION)
FIGURE 37. VITROLIFE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 38. VITROLIFE: REVENUE SHARE BY REGION, 2020(%)
Companies Mentioned
- Cook Medical Inc.
- Fujifilm Holdings Corporation (Irvine Scientific Sales Company Inc.)
- Genea Biomedx
- Merck KGaA (EMD Serono Inc.)
- Millendo Therapeutics Inc.
- Oxford Gene Technology
- Progyny Inc.
- The Cooper Companies Inc. (CooperSurgical Inc.)
- Thermo Fisher Scientific, Inc.,
- Vitrolife AB.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
